Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
January 03, 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Completes Exit from Laboratory Business with Sale of Affiliate Lab
December 20, 2021 16:05 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
New Study Shows Patients With Irritable Bowel Syndrome and Functional Dyspepsia Experience High Levels of Bloating and Distension
December 09, 2021 09:00 ET
|
Rome Foundation
RALEIGH, N.C., Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation Research Institute and Danone Nutricia Research have partnered on a study to look at the prevalence of bloating and distension in...
Sonic Incytes Medical Corp. Successfully Completes Series A Raise of US$7.3M to Accelerate Velacur™ Commercialization
December 07, 2021 10:00 ET
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M...
Progenity Announces New Patent for Single-Molecule Detection Technology
December 02, 2021 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today announced a...
Rome Foundation Releases Clinical Criteria to Better Meet Needs of Patients
November 29, 2021 09:00 ET
|
Rome Foundation
RALEIGH, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation has published a groundbreaking modification of the Rome IV diagnostic criteria of the Disorders of Gut Brain Interaction (DGBI -...
Progenity Strengthens its Liquidity Position
November 23, 2021 06:30 ET
|
Progenity, Inc.
Company received more than $44 million in warrant exercises since August 2021. Current liquidity position provides runway to achieve critical research and development milestones through 2022. SAN...
Progenity to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in a pre-recorded fireside chat at...
Velacur™ Data Presented at 2021 AASLD The Liver Meeting®
November 12, 2021 08:00 ET
|
Sonic Incytes Medical Corp.
VANCOUVER, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health...
Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 10, 2021 16:01 ET
|
Progenity, Inc.
Added important patents further protecting the company’s therapeutic delivery technologiesAdded strong biotherapeutics capabilities to management team and board of directorsImplemented cost-cutting...